EUVIMEDEUVIMED entdecken
Crossref

Assessment of BCL ‐2 expression in bone marrow by flow cytometry to aid in the diagnosis and differential diagnosis in patients with follicular lymphoma

Lu-Yang Li iD, Ting Liang, Xiao-Lan Liu, Xiao-Lian Wen, Li-Yuan Qin, Hong-Wei Zhang, Jing Li, Yu-Run Du, Jia-Hui Hou, Rui-Han Gao, Li-Ping Su, Bao-Feng Yu und 1 weitere

Cytometry Part B: Clinical Cytometry · 30.10.2026

DOI: 10.1002/cyto.b.70089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 30.10.2026. Verfasst von Lu-Yang Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Basic Medicine, Shanxi Medical University, Key Laboratory of Cell Physiology, Ministry of…. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Natural Science Basic Project of Shanxi Province, Project of Shanxi Key Laboratory, Shanxi Provincial Department of Science and Technology, Open Fund of the Key Laboratory of Cellular Physiology, Ministry of Education (Shanxi Medical University).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follicular lymphoma (FL) is a common indolent non‐Hodgkin's lymphoma (NHL), with 40%–70% of newly diagnosed patients presenting bone marrow infiltration (BMI). Accurate diagnosis and differential diagnosis based on bone marrow are particularly important. High BCL‐2 expression is a characteristic feature of FL, but the utility of flow cytometry (FCM) for evaluating BCL‐2 expression in bone marrow aspirates has not been well established. Two hundred and sixty‐five FL patients were enrolled and divided into BD cohort and BECKMAN cohort (new diagnosed: n = 230; relapsed/refractory: n = 35). BCL‐2 expression was investigated using the BCL‐2 mean fluorescence intensity (MFI), BCL‐2 percentage, and BCL‐2:CD200 ratio. Patients with FCM‐detectable clonal B cells (FCM (+)) were compared with those without detectable involvement (FCM (−)) for immunophenotypic features and progression‐free survival (PFS). FCM (+) patients showed a characteristic immunophenotype, including CD10 (+), CD19 (dim+), CD20 (dim+), CD22 (dim+), CD200 (−). Compared with FCM (−) patients, FCM (+) patients had higher BCL‐2 MFI, BCL‐2 percentage, and BCL‐2:CD200 ratio, and significantly shorter PFS. Among the three BCL‐2‐related parameters, BCL‐2 percentage showed the highest area under the curve for discriminating FCM (+) from FCM (−) cases, followed by the BCL‐2:CD200 ratio and BCL‐2 MFI. Notably, among FCM (+) patients, higher BCL‐2 expression was associated with longer PFS. Among FCM (+) patients, BCL‐2 expression was higher in FL than other indolent NHLs (CLL: n = 6, MZL: n = 4, and MCL: n = 3). The results were all consistent between the BD cohort and BECKMAN cohort. We confirmed that detecting BCL‐2 expression levels in the bone marrow aspirate of FL patients by FCM can aid in the diagnosis of FL, potentially assisting in distinguishing FL from other indolent NHLs, and exploratory assessment of PFS.

Schlagwörter

Stichwörter der Autor:innen

BCL‐2bone marrowclonal B cellsflow cytometryfollicular lymphomamean fluorescence intensity

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, School of Basic Medicine, Shanxi Medical University, Key Laboratory of Cell Physiology, Ministry of Education, Taiyuan, China.
  • Department of Hematology, Affiliated Cancer Hospital of Shanxi Medical University/Shanxi Provincial Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy, Taiyuan, China.
  • Shanxi Provincial Key Laboratory of Lymphoma Precision Diagnosis and Treatment Research, Taiyuan, China.
  • Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, China.
  • Department of Pathology, Affiliated Cancer Hospital of Shanxi Medical University/Shanxi Provincial Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy, Taiyuan, China.
  • The Second Clinical Medical College of Shanxi Medical University, Taiyuan, China.

ORCID-Profile: Lu-Yang Li

Förderung

  • Natural Science Basic Project of Shanxi Province
  • Project of Shanxi Key Laboratory, Shanxi Provincial Department of Science and Technology
  • Open Fund of the Key Laboratory of Cellular Physiology, Ministry of Education (Shanxi Medical University)
  • Science and Technology Guidance Special Project of the "Ten-Billion-Yuan Project" for Higher Education in Shanxi Province

Zitieren

APA

Li, L. Y., Liang, T., Liu, X. L., Wen, X. L., Qin, L. Y., Zhang, H. W., Li, J., Du, Y. R., Hou, J. H., Gao, R. H., Su, L. P., Yu, B. F., & Guan, T. (2026). Assessment of BCL ‐2 expression in bone marrow by flow cytometry to aid in the diagnosis and differential diagnosis in patients with follicular lymphoma. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.70089

Vancouver

Li LY, Liang T, Liu XL, Wen XL, Qin LY, Zhang HW, et al. Assessment of BCL ‐2 expression in bone marrow by flow cytometry to aid in the diagnosis and differential diagnosis in patients with follicular lymphoma. Cytometry Part B: Clinical Cytometry. 2026. doi:10.1002/cyto.b.70089

BibTeX
@article{Li2026,
  author = {Li, Lu-Yang and Liang, Ting and Liu, Xiao-Lan and Wen, Xiao-Lian and Qin, Li-Yuan and Zhang, Hong-Wei and Li, Jing and Du, Yu-Run and Hou, Jia-Hui and Gao, Rui-Han and Su, Li-Ping and Yu, Bao-Feng and Guan, Tao},
  title = {Assessment of BCL ‐2 expression in bone marrow by flow cytometry to aid in the diagnosis and differential diagnosis in patients with follicular lymphoma},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2026},
  doi = {10.1002/cyto.b.70089}
}
Kostenlos starten →